ArticleFrontiers in microbiology2022
CARB-ES-19 Multicenter Study of Carbapenemase-Producing
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Surveillance of antibiotic-resistant bacteria integrating whole genome sequencing and epidemiological information - a global, systematic review, 2012-2023.Antimicrobial resistance and infection control · 2026Pooled it
- Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.PLoS medicine · 2023Pooled it
- FTIR typing of the emerging NDM-14-producingJournal of clinical microbiology · 2026Article
- Trends in the Frequency and Antimicrobial Resistance of Common Gram-Negative Bacilli Isolated From Urine Cultures.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Clonal dissemination and plasmid plasticity of KPC-3-producing Klebsiella pneumoniae ST512 during a hospital outbreak in Spain.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The Wildlife-Livestock Interface as a Bidirectional Pathway for the Spread of ESBL-ProducingAnimals : an open access journal from MDPI · 2026Review
- Clinical Impact of OXA-48-Producing Enterobacterales Rectal Colonization on Hematologic Patients With Febrile Neutropenia.Open forum infectious diseases · 2026Article
- Article
- Phage-meropenem synergy against OXA-48-producing Klebsiella pneumoniae clinical isolates.npj antimicrobials and resistance · 2026Article
- Bloodstream Infections Due to Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2026Review
- Multidrug-resistant gram-negative bacteria in Spanish ICU patients: clinical and microbiological characterization (MURAN-UCI Project).Microbiology spectrum · 2026Article
- Effects of phage-based treatments against an OXA-48-producing Klebsiella pneumoniae isolate in simulated human gut microbiomes.BMC microbiology · 2026Article
- Genomic and virulence characterization of OXA-48-producingFrontiers in microbiology · 2026Article
- Emergence of OXA-48-producingFrontiers in cellular and infection microbiology · 2026Article
- Resistance to novel antimicrobial agents among NDM-and OXA-48-producing Carbapenem-resistant Enterobacterales in Lebanon.Frontiers in cellular and infection microbiology · 2026Article
- Pharmacokinetic/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producingAntimicrobial agents and chemotherapy · 2025Article
- A capsule-dependent lytic phage for targeting multidrug-resistant and hypervirulentApplied and environmental microbiology · 2025Article
- Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.Antimicrobial agents and chemotherapy · 2025Article
- Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework.Infectious diseases and therapy · 2025Article
- Cefiderocol-resistant pathogens in German hospital wastewater: a reservoir for multidrug resistance.Scientific reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis. Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were Conclusion: This study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.